title: Future directions for peptide therapeutics development.
abstract: The notable expansion of peptide therapeutics development in the late 1990s and the 2000s led to an unprecedented number of marketing approvals in 2012 and has provided a robust pipeline that should deliver numerous approvals during the remainder of the 2010s. To document the current status of the pipeline, we collected data for peptide therapeutics in clinical studies and regulatory review, as well as those recently approved. In this Foundation review, we provide an overview of the pipeline, including therapeutic area and molecular targets, with a focus on glucagon-like peptide 1 receptor agonists. Areas for potential expansion, for example constrained peptides and peptide-drug conjugates, are profiled.
authors.affiliation: CovX/Pfizer Worldwide Research and Development, 9381 Judicial Drive, Suite 200, San Diego, CA 92121, USA.
authors.forename: Allan A
authors.initials: AA
authors.lastname: Kaspar
authors.forename: Janice M
authors.initials: JM
authors.lastname: Reichert
mesh_terms: D000818:Animals; D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends*; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D005544:Forecasting; D006801:Humans; D058990:Molecular Targeted Therapy / Q000639:trends; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D015507:Drugs, Investigational; D010455:Peptides